Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment-Reference-Cited by-同舟云学术

Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment

Published:2017-04 Issue:2 Volume:40 Page:200-206
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Pervez Nadeem,Boychak Alex,Drodge Claudia S.,Yee Don,Le Duc,Murtha Albert,Parliament Matthew,Amanie John,Mihai Alina,Field Colin,Mackenzie Marc,Ghosh Sunita,Fallone Gino,Pearcey Robert

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference28 articles.

1. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial;Denham;Lancet Oncol,2005

2. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial;Bolla;Lancet,2002

3. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09;Zietman;J Clin Oncol,2010

4. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial;Dearnaley;Lancet Oncol,2012

5. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue;Brenner;Int J Radiat Oncol Biol Phys,2002

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolérance à court et moyen terme d’une radiothérapie prostatique hypofractionnée selon la technique du boost intégré;Cancer/Radiothérapie;2024-08

2. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer;Clinical and Translational Radiation Oncology;2024-01

3. Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2022-08

4. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity;Clinical Oncology;2022-01

5. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer;Practical Radiation Oncology;2021-09